Mitsubishi Tanabe Pharma America to Present New ALS Research at MNDA’s 35th International Symposium on ALS/MND | PR Newswire [Video]

, /PRNewswire/ — Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 10 presentations covering advances in amyotrophic lateral sclerosis (ALS) research at the Motor Neurone Disease Association (MNDA) 35^th International Symposium on ALS/MND, being held in Montreal, Canada, from December 6-8. 

“We are honored to participate in this year’s MNDA symposium, where we will share insights from our preclinical, clinical and real-world studies on RADICAVA^® (edaravone) and RADICAVA ORS^® (edaravone) and discuss the evolving ALS treatment landscape,” said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. “Our commitment to advancing ALS research is underscored by over eight years of continuous contributions at this symposium. This dedication guides us in leveraging both clinical and real-world evidence to help support the ALS community.”

RADICAVA ORS Results:

Final results from two multi-center, Phase 3b, double-blind, parallel group studies will be presented, including a comparison of daily dosing of RADICAVA ORS (edaravone) with the …